Predictions of arrhythmic, heart failure and mortality outcomes in pericarditis using automatic electrocardiogram analysis

Ishan Lakhani * ¹, Jiandong Zhou * ², Michelle Vangi Wong ¹, Sharen Lee ^{1,3}, Jovy Ka Yiu Lau
BSc ¹, Silverdew Shi ¹, Wing Tak Wong PhD ⁴, Tong Liu MD PhD ⁵, Qingpeng Zhang PhD * ²,
Gary Tse PhD FRCP FFPH * ⁴

¹ Cardiovascular Analytics Group, Laboratory of Cardiovascular Physiology, Hong Kong, China

² School of Data Science, City University of Hong Kong, Hong Kong, Hong Kong, China

³ Li Ka Shing Institute of Health Sciences, Hong Kong, China

⁴ School of Life Sciences, Chinese University of Hong Kong, Hong Kong S.A.R., China

⁵ Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China

⁶ Faculty of Health and Medical Sciences, University of Surrey, GU2 7AL, Guildford, United Kingdom

** equal contributions as first authors*

Dr. Gary Tse, PhD, FRCP, FFPH

Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, People's Republic of China, China

Faculty of Health and Medical Sciences, University of Surrey, GU2 7AL, Guildford, United Kingdom

Email: g.tse@surrey.ac.uk / garytse86@gmail.com

Dr. Qingpeng Zhang, PhD

School of Data Science, City University of Hong Kong,

Hong Kong SAR, China

Email: qingpeng.zhang@cityu.edu.hk

Abstract

Background:

Pericarditis is a relatively rare disease with a global burden. Despite its strong association with adverse cardiovascular outcomes, identification of patients at risk of future heart failure or arrhythmic events is difficult. In the following study, automated electrocardiogram (ECG) were used to predict new onset ventricular tachycardia/fibrillation (VT/VF), atrial fibrillation (AF) and heart failure with reduced ejection fraction (HF) in an Asian cohort of pericarditis patients.

Methods: Consecutive patients admitted to a single tertiary center in Hong Kong, China, for a diagnosis of pericarditis between 1st January 2005 and 31st December 2019 with baseline ECG measurements were included. Patients with existing AF or HF were excluded. The follow-up period was until the 31st December 2020, or death. Cox regression was applied to identify significant predictors of the primary outcomes (incident VT/VF, AF or HF).

Results: A total of 874 patients were included. The cohort was 57% male and had a median age of 59 (IQR: 50-70) years old. During follow-up, 57 patients (6.5%), 156 (17.8%) and 168 (19.2%) suffered from VT/VF, AF and HF, respectively. Cox regression identified baseline VT/VF, terminal angle of the QRS vector in the transverse plane, mean QRS duration and mean QTc intervals as significant predictors of incident VT/VF events, with only the former most maintaining significance in multivariate analysis. In contrast, baseline age, prior diagnoses of hypertension, initial angle and magnitude of the QRS vector in the transverse

plane, P-wave and QRS axis in the frontal plane, ST segment axis in the frontal and horizontal planes, mean PT interval, mean PR segment duration and QTc intervals were all univariate predictors of incident AF, albeit only baseline age and initial angle of the QRS vector in the transverse plane retained significance after multivariate adjustment. As it pertains to new-onset HF, several clinical and electrocardiographic parameters demonstrated an association with HF in univariate analysis, with prior diagnosis of HT or DM, initial QRS angle in transverse plane, I 40 in horizontal axis, ST-segment axis in the horizontal plane, T-wave frontal axis and atrial rate, of which, except for prior diagnosis of DM, I40 in horizontal axis and T-wave frontal axis, all variables showcased significant relationships in multivariate analysis

Interpretation: AF and HF are relatively common complications VT/VF occurs less frequently in the context of pericarditis. Different clinical and ECG predictors of these outcomes were identified. Future studies are still needed to evaluate their use for risk stratification in the clinical setting.

Introduction

Acute pericarditis, an inflammation of the pericardial layer of the heart, is an immune-mediated clinical condition that is often unrecognized and associated with numerous of complications ¹. Previous cohort studies have explored the aetiology ², clinical presentation ^{3,4} and risk factors leading to readmission ⁵, composite of cardiac tamponade, constrictive pericarditis, failed therapy, recurrence and mortality ⁶. By contrast, few studies have explored atrial or ventricular arrhythmic outcomes. Moreover, recent studies have reported the roles of automated electrocardiogram (ECG) analysis to facilitate risk stratification and prediction. However, few studies have examined the roles of ECG predictors for adverse outcomes in the pericarditis population. Therefore, the aim of this study is to investigate the predictive roles of automated electrocardiograms (ECG) for predicting new onset atrial fibrillation (AF), ventricular tachycardia/fibrillation (VT/VF) or heart failure (HF) in a cohort of pericarditis patients admitted to a single tertiary centre.

Methods

Study design and population

The study was approved by The Joint Chinese University of Hong Kong – New Territories East Cluster Clinical Research Ethics Committee. This was a retrospective, territory-wide cohort study of pericarditis patients with baseline ECG measurements from 1st January 2005 to 31st December 2019 admitted to a single tertiary center from the Hong Kong region of China. The patients were identified from the Clinical Data Analysis and Reporting System (CDARS), a

territory-wide database that centralizes patient information from 43 local hospitals and their associated ambulatory and outpatient facilities to establish comprehensive medical data, including clinical characteristics, disease diagnosis, laboratory results, and drug treatment details. The system has been previously used by both our team and other teams in Hong Kong^{7,8}. Patients' demographics, prior comorbidities, medication prescriptions, laboratory examinations of complete blood counts, biochemical liver and renal tests, lipid and glucose tests and cardiac function tests, and ECG measurements were extracted. The list of ICD-9 codes for comorbidities and outcomes were detailed in the **Supplementary Table 1**.

Baseline characteristics and ECG measurements

Clinical data was extracted from electronic health records. The following baseline clinical data were collected: 1) sex; 2) age of initial Brugada pattern presentation; 3) follow-up period; 4) type of Brugada pattern and presence of fever at initial presentation; 5) family history of BrS and VF/ SCD; 6) manifestation of syncope and if present, the number of episodes; 7) manifestation of VT/VF and if present, the number of episodes; 8) sodium channel blocker challenge test and results; 9) concomitant presence of other arrhythmia; 10) implantation of ICD. Patients presented with two or more episodes of VT/VF were defined to be of high VT/VF burden. Automatically measured parameters from ECG related to the P, Q, R, S and T-wave were extracted. This has been done previously by our team and further details could be found here ^{9,10}.

Outcomes and statistical analysis

The primary outcome was new onset VT/VF. Secondary outcomes included new onset 1) AF, 2) new-onset HFrEF and 3) all-cause mortality. The secondary outcomes were cardiovascular mortality and all-cause mortality. Mortality data were obtained from the Hong Kong Death Registry, a population-based official government registry with the registered death records of all Hong Kong citizens linked to CDARS. There was no adjudication of the outcomes as this relied on the ICD-9 coding or a record in the death registry. However, the coding was performed by the clinicians or administrative staff, who were not involved in the model development. Descriptive statistics are used to summarize baseline clinical characteristics of all pericarditis patients and based on the occurrence of the primary and secondary outcomes. Continuous variables were presented as median (95% confidence interval[CI] or interquartile range[IQR]) and categorical variables were presented as count (%). The Mann-Whitney U test was used to compare continuous variables. The χ^2 test with Yates' correction was used for 2×2 contingency data. Univariate logistic regression identifies significant mortality risk predictors. Hazard ratios (HRs) with corresponding 95% CIs and P-values were reported. There was no imputation performed for missing data. No blinding was performed for the predictor as the values were obtained from the electronic health records automatically. All statistical tests were two-tailed and considered significant if p value < 0.001. They were performed using RStudio software (Version: 1.1.456) and Python (Version: 3.6).

Results

Basic characteristics

The baseline clinical characteristics of patients with/without spontaneous VT/VF are presented in **Table 1**. Subjects who developed incident VT/VF tended to have baseline VT/VF prior to the diagnosis of pericarditis. Regarding blood parameters, these individuals also reported significantly higher eosinophil counts, low-density-lipoprotein (LDL) levels, high-sensitivity troponin I (hsTnI) levels and lactate dehydrogenase (LDH) levels, as well as a lower mean corpuscular volume (MCV). Patients who developed VT/VF likewise had greater terminal QRS angles in the transverse plane and T-wave frontal axis, along with a longer QTc interval.

Predictors of primary and secondary outcomes

A total of 874 patients were included. The cohort was 57% male and had a median age of 59 (IQR: 50-70) years old. During follow-up, 57 patients (6.5%), 156 (17.8%) and 168 (19.2%) suffered from VT/VF, AF and HF, respectively. Cox regression identified baseline VT/VF, terminal angle of the QRS vector in the transverse plane, mean QRS duration and mean QTc intervals as significant predictors of incident VT/VF events, with only the former most maintaining significance in multivariate analysis (HR: 5.03; 95% CI: 1.12 – 22.6; P = 0.035). In contrast, regarding secondary outcomes, baseline age, prior diagnoses of hypertension, initial angle and magnitude of the QRS vector in the transverse plane, P-wave and QRS axis in the frontal plane, ST segment axis in the frontal and horizontal planes, mean PT interval,

mean PR segment duration and QTc intervals were all univariate predictors of incident AF, albeit only baseline age (HR: 1.03; 95% CI: 1.02 – 1.05; $P < 0.001$) and initial angle of the QRS vector in the transverse plane (HR: 1.003; 95% CI: 1.001 – 1.005; $P = 0.003$) retained significance after multivariate adjustment. As it pertains to new-onset HF, several clinical and electrocardiographic parameters demonstrated an association with HF in univariate analysis, including prior diagnosis of HT (HR: 3.27; 95% CI: 2.08 – 5.13; $P < 0.001$) or DM, initial QRS angle in transverse plane (HR: 1.002; 95% CI: 1.001 – 1.004; $P = 0.008$), I 40 in horizontal axis, ST-segment axis in the horizontal plane (HR: 1.004; 95% CI: 1.001 – 1.009; $P = 0.008$), T-wave frontal axis and atrial rate (HR: 1.01; 95% CI: 1.006 – 1.014; $P < 0.001$), of which, except for prior diagnosis of DM, I40 in horizontal axis and T-wave frontal axis, all variables showcased significant relationships in multivariate analysis.

A total of 396 (45%) patients died during follow-up, of which 52 (6%) were cardiovascular-related. Univariate predictors for all-cause mortality comprised baseline age, prior diagnosis of hypertension, terminal and maximum magnitude of the QRS vector in the transverse plane, T wave (40ms) horizontal axis, ventricular rate mean QTc interval, mean PT interval, mean PR segment and QT interval dispersion. Subsequent multivariate adjustment revealed only significant associations for only baseline age (HR: 1.02; 95% CI: 1.01-1.03; $P < 0.001$) and maximum magnitude of the QRS vector in the transverse plane (HR: 0.55; 95% CI: 0.4-0.75; $P < 0.001$).

Discussion

The major limitation of this study is that it is based on a single centre cohort. We recognize that the derivation populations may differ from other populations based both on hospital conditions and inherent demographic differences. An external validation using independent external cohort allows us to assess the broader clinical utility of our findings. However, the model should be further externally validated using patient data from other regions.

Conflicts of Interest

None.

References

- 1 Chiabrando, J. G. *et al.* Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. *J Am Coll Cardio***75**, 76-92, doi:10.1016/j.jacc.2019.11.021 (2020).
- 2 Sathirareuangchai, S., Kobayashi, M. & Shimizu, D. Etiologies of pericarditis in hospital and forensic autopsies. *Cardiovasc Pathol***49**, 107262, doi:10.1016/j.carpath.2020.107262 (2020).
- 3 Imazio, M. *et al.* Myopericarditis versus viral or idiopathic acute pericarditis. *Heart***94**, 498-501, doi:10.1136/hrt.2006.104067 (2008).
- 4 Kyto, V., Sipila, J. & Rautava, P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. *Circulation***130**, 1601-1606, doi:10.1161/CIRCULATIONAHA.114.010376 (2014).
- 5 Sreenivasan, J. *et al.* Rate, Causes, and Predictors of 30-Day Readmission Following Hospitalization for Acute Pericarditis. *Am J Med***133**, 1453-1459 e1451, doi:10.1016/j.amjmed.2020.05.027 (2020).
- 6 Vecchie, A. *et al.* Clinical Presentation and Outcomes of Acute Pericarditis in a Large Urban Hospital in the United States of America. *Chest***158**, 2556-2567, doi:10.1016/j.chest.2020.07.039 (2020).
- 7 Zhou, J. *et al.* Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study. *Gut*, doi:10.1136/gutjnl-2020-323668 (2020).

- 8 Lee, S. *et al.* Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning. *BMC Endocr Disord***21**, 94, doi:10.1186/s12902-021-00751-4 (2021).
- 9 Tse, G. *et al.* P-Wave Area Predicts New Onset Atrial Fibrillation in Mitral Stenosis: A Machine Learning Approach. *Front Bioeng Biotechnol***8**, 479, doi:10.3389/fbioe.2020.00479 (2020).
- 10 Tse, G. *et al.* Automated Electrocardiogram Analysis Identifies Novel Predictors of Ventricular Arrhythmias in Brugada Syndrome. *Frontiers in Cardiovascular Medicine***7**, 399 (2021).

Table 1. Baseline clinical characteristics of patients with/without spontaneous VT/VF.* for $p \leq 0.05$, ** for $p \leq 0.01$, *** for $p \leq 0.001$.

indicates that the comparisons were made between patients with/without spontaneous VT/VF.

Characteristics	All patients (N=874) Median (IQR);N or Count(%)	Spontaneous VT/VF (N=57) Median (IQR);N or Count(%)	No spontaneous VT/VF (N=817) Median (IQR);N or Count(%)	P value [#]
<i>Demographics</i>				
Male gender	494(56.52%)	30(52.63%)	464(56.79%)	0.8325
Female gender	380(43.47%)	27(47.36%)	353(43.20%)	0.7972
Baseline age, years	59.43(49.5-69.76);n=874	58.84(47.25-68.06);n=57	59.51(49.82-69.86);n=817	0.477
<40	119(13.61%)	12(21.05%)	107(13.09%)	0.2144
[40, 50)	105(12.01%)	6(10.52%)	99(12.11%)	0.9139
[50-60)	221(25.28%)	13(22.80%)	208(25.45%)	0.8468
[60-70)	216(24.71%)	14(24.56%)	202(24.72%)	0.8946
[70-80)	145(16.59%)	10(17.54%)	135(16.52%)	0.9902
>=80	68(7.78%)	2(3.50%)	66(8.07%)	0.3607
Charlson standard comorbidity index	2.0(1.0-4.0);n=874	2.0(0.0-4.0);n=57	2.0(1.0-4.0);n=817	0.3003
<i>Past comorbidities</i>				
Baseline VT/VF	8(0.91%)	4(7.01%)	4(0.48%)	<0.0001***
Cerebrovascular disease	28(3.20%)	2(3.50%)	26(3.18%)	0.7969
Rheumatic disease	22(2.51%)	4(7.01%)	18(2.20%)	0.0862
Renal diseases	48(5.49%)	3(5.26%)	45(5.50%)	0.821
Diabetes mellitus	25(2.86%)	3(5.26%)	22(2.69%)	0.4992
Hypertension	155(17.73%)	11(19.29%)	144(17.62%)	0.9281
AMI	23(2.63%)	0(0.00%)	23(2.81%)	0.405

COPD	8(0.91%)	1(1.75%)	7(0.85%)	0.9702
IHD	86(9.83%)	6(10.52%)	80(9.79%)	0.9477
PVD	12(1.37%)	1(1.75%)	11(1.34%)	0.7372
Stroke/TIA	25(2.86%)	2(3.50%)	23(2.81%)	0.9082
Gastrointestinal bleeding	39(4.46%)	2(3.50%)	37(4.52%)	0.9892
Immune mediated enterocolitis	47(5.37%)	2(3.50%)	45(5.50%)	0.7547
Anxiety disorder and depression	17(1.94%)	1(1.75%)	16(1.95%)	0.6962
SCD	25(2.86%)	1(1.75%)	24(2.93%)	0.9257
Atrial flutter	6(0.68%)	0(0.00%)	6(0.73%)	0.853
Accident fall	50(5.72%)	3(5.26%)	47(5.75%)	0.8812
Malignancy	165(18.87%)	8(14.03%)	157(19.21%)	0.523
Metastatic solid tumor	94(10.75%)	2(3.50%)	92(11.26%)	0.1429
<i>Medications</i>				
ACEI	77(8.81%)	7(12.28%)	70(8.56%)	0.5317
ARB	30(3.43%)	5(8.77%)	25(3.05%)	0.0728
Lipid-lowering drugs	-	-	-	-
Anticoagulants	100(11.44%)	11(19.29%)	89(10.89%)	0.145
Insulin	-	-	-	-
Incretin mimetics	10(1.14%)	1(1.75%)	9(1.10%)	0.8411
<i>Complete blood counts</i>				
Mean corpuscular volume, fL	89.8(86.3-93.35);n=543	88.5(85.0-90.6);n=37	90.0(86.4-93.5);n=506	0.0367*
Eosinophil, x10 ⁹ /L	0.1(0.0-0.2);n=504	0.2(0.1-0.3);n=33	0.1(0.0-0.2);n=471	0.0008***

Lymphocyte, x10 ⁹ /L	1.15(0.8-1.7);n=505	1.1(0.8-1.6);n=33	1.15(0.8-1.7);n=472	0.9463
Monocyte, x10 ⁹ /L	0.6(0.4-0.8);n=505	0.7(0.5-0.9);n=33	0.6(0.4-0.77);n=472	0.0509
Neutrophil, x10 ⁹ /L	4.9(3.4-7.7);n=505	5.2(4.1-6.6);n=33	4.9(3.4-7.75);n=472	0.5897
White cell count, x10 ⁹ /L	7.0(5.5-9.15);n=543	7.6(6.5-10.1);n=37	6.95(5.5-9.0);n=506	0.056
Mean cell haemoglobin, pg	30.6(29.0-32.0);n=543	29.7(28.5-31.3);n=37	30.7(29.1-32.1);n=506	0.0608
Platelet, x10 ⁹ /L	212.0(166.5-275.0);n=543	243.0(197.0-294.0);n=37	209.0(165.0-274.0);n=506	0.0958
Red blood count, x10 ¹² /L	4.09(3.6-4.58);n=543	4.1(3.4-4.53);n=37	4.08(3.6-4.58);n=506	0.6528

Liver and renal functions

K/Potassium, mmol/L	4.0(3.7-4.4);n=684	4.0(3.6-4.35);n=52	4.0(3.7-4.4);n=632	0.5585
Urate, mmol/L	0.38(0.28-0.49);n=100	0.34(0.24-0.59);n=13	0.38(0.28-0.47);n=87	0.7701
Albumin, g/L	35.9(30.5-40.0);n=681	34.85(31.2-39.15);n=52	35.9(30.5-40.1);n=629	0.6382
Na/Sodium, mmol/L	138.45(135.2-140.9);n=684	138.8(136.05-140.75);n=52	138.4(135.05-140.9);n=632	0.7475
Urea, mmol/L	5.8(4.26-8.41);n=683	6.02(4.12-12.04);n=52	5.73(4.27-8.4);n=631	0.6471
Protein, g/L	71.0(65.6-75.4);n=681	71.25(67.05-75.35);n=52	71.0(65.5-75.4);n=629	0.9386
Creatinine, umol/L	84.0(66.0-113.0);n=682	89.0(59.5-122.0);n=51	83.0(66.0-111.5);n=631	0.7487
Alkaline phosphatase, U/L	82.0(65.0-118.0);n=681	85.0(69.0-118.5);n=52	82.0(64.0-118.0);n=629	0.4949
Aspartate transaminase, U/L	29.5(18.0-58.1);n=82	29.0(17.0-47.0);n=10	29.5(18.0-62.5);n=72	0.6967
Alanine transaminase, U/L	24.0(16.0-44.0);n=681	19.5(14.0-44.5);n=52	24.0(16.0-44.0);n=629	0.1168
Bilirubin, umol/L	10.4(6.9-16.8);n=681	8.35(6.0-13.0);n=52	10.6(7.0-17.0);n=629	0.0766

Lipid and glucose tests

Triglyceride, mmol/L	1.01(0.75-1.44);n=167	1.47(1.23-1.6);n=13	1.0(0.74-1.42);n=154	0.0864
Low-density lipoprotein, mmol/L	2.22(1.61-2.86);n=153	2.45(1.66-2.86);n=11	2.22(1.62-2.84);n=142	0.9859
High-density lipoprotein, mmol/L	1.07(0.81-1.41);n=153	0.86(0.78-1.0);n=11	1.12(0.82-1.48);n=142	0.0273*

Cholesterol, mmol/L	3.82(3.15-4.72);n=167	4.05(3.42-4.82);n=13	3.82(3.15-4.71);n=154	0.9167
HbA1c, g/dL	12.3(10.8-13.7);n=543	11.4(10.6-13.7);n=37	12.3(10.8-13.7);n=506	0.3974
Glucose, mmol/L	6.41(5.44-8.16);n=467	6.65(5.73-7.9);n=36	6.4(5.43-8.2);n=431	0.5478
<i>Cardiac, clotting, inflammatory, and acid-base tests</i>				
D-dimer, ng/mL	2666.0(1276.23-6132.04);n=73	2422.73(2332.06-3120.41);n=9	2684.52(1164.69-6470.84);n=64	0.9131
High sensitive troponin-I, ng/L	0.02(0.01-0.07);n=444	0.04(0.02-0.16);n=32	0.02(0.01-0.07);n=412	0.0155*
Lactate dehydrogenase, U/L	265.0(211.0-387.5);n=483	304.5(233.0-440.5);n=36	262.0(207.0-371.5);n=447	0.0428*
APTT, second	33.0(30.2-36.6);n=721	34.5(30.7-37.0);n=53	33.0(30.2-36.45);n=668	0.1871
Prothrombin time/INR, second	11.9(10.8-13.7);n=721	11.7(10.4-13.3);n=53	11.9(10.8-13.7);n=668	0.4269
C-reactive protein, mg/dL	2.91(0.56-8.62);n=556	3.76(0.73-7.04);n=40	2.78(0.56-8.67);n=516	0.6553
<i>ECG measurements</i>				
Trans QRS initangle	42.0(19.0-90.0);n=574	38.5(14.0-94.0);n=36	42.0(19.0-90.0);n=538	0.5997
Trans QRS initmag	0.31(0.18-0.5);n=574	0.33(0.15-0.48);n=36	0.31(0.18-0.5);n=538	0.8278
Trans QRS max angle	331.0(42.5-347.0);n=574	323.0(76.0-348.0);n=36	331.0(42.5-347.0);n=538	0.5825
Trans QRS max mag	1.23(0.86-1.66);n=574	1.15(0.85-1.63);n=36	1.23(0.86-1.66);n=538	0.4962
Trans QRS term angle	243.0(214.0-273.0);n=574	225.5(201.0-248.5);n=36	244.0(215.5-273.0);n=538	0.0183*
Trans QRS term mag	0.3(0.2-0.41);n=574	0.3(0.24-0.51);n=36	0.3(0.19-0.41);n=538	0.2255
Trans QRS cwrot	-100.0(-100.0--87.5);n=574	-100.0(-100.0--10.0);n=36	-100.0(-100.0--100.0);n=538	0.3281
P wave front axis	54.0(39.0-68.0);n=798	54.5(40.0-69.5);n=54	54.0(39.0-68.0);n=744	0.6899
P wave horizontal axis	20.0(4.0-37.0);n=830	21.0(3.0-35.0);n=55	20.0(4.0-37.0);n=775	0.7535
I 40 front axis	38.0(15.0-58.0);n=860	34.0(8.5-53.0);n=55	38.0(15.0-58.0);n=805	0.177

I 40 horizon axis	28.0(11.5-44.0);n=839	28.0(17.0-48.5);n=55	28.0(11.0-44.0);n=784	0.4206
QRS front axis	52.0(20.0-75.0);n=871	48.0(10.0-79.0);n=57	52.0(21.0-75.0);n=814	0.7057
QRS horizon axis	-11.0(-30.0-9.0);n=853	-8.0(-46.5-20.0);n=56	-11.0(-30.0-8.0);n=797	0.8747
T wave 40ms front axis	69.0(19.0-101.5);n=862	84.0(8.0-118.0);n=57	69.0(19.0-100.0);n=805	0.2919
T wave 40ms horizon axis	-23.0(-52.0-184.0);n=829	-10.5(-55.0-211.0);n=56	-23.0(-52.0-179.0);n=773	0.5137
ST segment front axis	63.0(30.0-113.5);n=827	72.0(33.5-126.0);n=56	63.0(30.0-112.5);n=771	0.5575
ST segment horizon axis	76.0(50.0-118.0);n=780	79.0(51.0-143.5);n=51	76.0(50.0-117.0);n=729	0.4827
T wave front axis	45.0(14.0-72.0);n=857	50.0(35.0-101.0);n=55	44.0(13.0-70.5);n=802	0.0322*
T wave horizon axis	46.0(25.0-76.0);n=805	48.0(16.0-84.0);n=53	46.0(25.0-75.5);n=752	0.8192
Atrial rate	80.0(67.0-99.5);n=874	83.0(75.0-92.0);n=57	80.0(66.0-100.0);n=817	0.6285
Mean ventricular rate	81.0(68.0-97.0);n=874	83.0(76.0-91.0);n=57	80.0(68.0-97.0);n=817	0.3177
Mean PT interval	161.0(144.5-177.5);n=874	160.0(148.0-178.0);n=57	161.0(144.0-177.0);n=817	0.649
Mean PR segment	63.0(48.0-78.0);n=874	64.0(48.0-78.0);n=57	63.0(49.0-78.0);n=817	0.8753
Mean QRS duration	85.0(78.0-95.0);n=874	86.0(81.0-100.0);n=57	85.0(78.0-94.0);n=817	0.0889
Mean QT interval	377.0(345.0-408.5);n=874	380.0(348.0-415.0);n=57	377.0(344.0-408.0);n=817	0.5507
Mean QTc interval	433.0(413.0-458.0);n=874	443.0(424.0-464.0);n=57	433.0(412.0-458.0);n=817	0.0202*
QT interval dispersion	64.0(0.0-104.0);n=874	60.0(0.0-104.0);n=57	64.0(0.0-104.0);n=817	0.686

COPD: chronic obstructive pulmonary disease; ACEI: angiotensinogen converting enzyme inhibitor; ARB: angiotensin receptor blocker; APTT: activated partial thromboplastin time.

* for $p \leq 0.05$, ** for $p \leq 0.01$, *** for $p \leq 0.001$.

Characteristics	New onset HF (N=168)	No new onset HF (N=706)	P value	New onset AF (N=156)	No new onset AF (N=718)	P value
	Median (IQR);N or Count(%)	Median (IQR);N or Count(%)		Median (IQR);N or Count(%)	Median (IQR);N or Count(%)	
Demographics						
Male gender	92(54.76%)	402(56.94%)	0.8421	86(55.12%)	408(56.82%)	0.8957
Female gender	76(45.23%)	304(43.05%)	0.8086	70(44.87%)	310(43.17%)	0.8711
Baseline age, years	66.33(57.07-77.3);n=168	57.69(47.94-68.03);n=706	<0.0001**	66.06(58.12-73.43);n=156	57.56(47.22-68.44);n=718	<0.0001**
<40	10(5.95%)	109(15.43%)	0.0058**	2(1.28%)	117(16.29%)	<0.0001**
[40, 50)	11(6.54%)	94(13.31%)	0.0397*	7(4.48%)	98(13.64%)	0.0056**
[50-60)	30(17.85%)	191(27.05%)	0.0642	40(25.64%)	181(25.20%)	0.9909
[60-70)	49(29.16%)	167(23.65%)	0.2954	54(34.61%)	162(22.56%)	0.0220*
[70-80)	39(23.21%)	106(15.01%)	0.0438*	35(22.43%)	110(15.32%)	0.0925
>=80	29(17.26%)	39(5.52%)	<0.0001**	18(11.53%)	50(6.96%)	0.109
Charlson standard comorbidity index	3.0(2.0-4.0);n=168	2.0(1.0-4.0);n=706	0.0005**	2.0(2.0-4.0);n=156	2.0(1.0-4.0);n=718	0.0205*
Past comorbidities						

s						
Baseline VT/VF	3(1.78%)	5(0.70%)	0.3939	1(0.64%)	7(0.97%)	0.9438
Cerebrovascular disease	9(5.35%)	19(2.69%)	0.1462	7(4.48%)	21(2.92%)	0.4724
Rheumatic disease	4(2.38%)	18(2.54%)	0.8794	3(1.92%)	19(2.64%)	0.8194
Renal diseases	14(8.33%)	34(4.81%)	0.1338	11(7.05%)	37(5.15%)	0.487
Diabetes mellitus	10(5.95%)	15(2.12%)	0.0206*	6(3.84%)	19(2.64%)	0.5995
Hypertension	54(32.14%)	101(14.30%)	<0.0001**	37(23.71%)	118(16.43%)	0.0972
AMI	9(5.35%)	14(1.98%)	0.0355*	4(2.56%)	19(2.64%)	0.8264
COPD	3(1.78%)	5(0.70%)	0.3939	1(0.64%)	7(0.97%)	0.9438
IHD	31(18.45%)	55(7.79%)	0.0004**	21(13.46%)	65(9.05%)	0.176
PVD	4(2.38%)	8(1.13%)	0.3897	3(1.92%)	9(1.25%)	0.793
Stroke/TIA	7(4.16%)	18(2.54%)	0.4027	7(4.48%)	18(2.50%)	0.3004
Gastrointestinal bleeding	10(5.95%)	29(4.10%)	0.4334	11(7.05%)	28(3.89%)	0.1541
Immune mediated enterocolitis	7(4.16%)	40(5.66%)	0.5851	7(4.48%)	40(5.57%)	0.7482
Anxiety disorder and	7(4.16%)	10(1.41%)	0.0514	2(1.28%)	15(2.08%)	0.7415

depression						
SCD	9(5.35%)	16(2.26%)	0.068	4(2.56%)	21(2.92%)	0.9786
Atrial flutter	2(1.19%)	4(0.56%)	0.7235	5(3.20%)	1(0.13%)	0.0003** *
Accident fall	11(6.54%)	39(5.52%)	0.7646	12(7.69%)	38(5.29%)	0.3637
Malignancy	9(5.35%)	156(22.09%)	<0.0001* **	13(8.33%)	152(21.16%)	0.0022**
Metastatic solid tumor	5(2.97%)	89(12.60%)	0.0014**	5(3.20%)	89(12.39%)	0.0031**
Medications						
ACEI	27(16.07%)	50(7.08%)	0.0016**	20(12.82%)	57(7.93%)	0.1081
ARB	9(5.35%)	21(2.97%)	0.2191	9(5.76%)	21(2.92%)	0.146
Lipid-lowering drugs	-	-	-	-	-	-
Anticoagulants	33(19.64%)	67(9.49%)	0.0020**	27(17.30%)	73(10.16%)	0.0372*
Insulin	-	-	-	-	-	-
Incretin mimetics	4(2.38%)	6(0.84%)	0.2118	1(0.64%)	9(1.25%)	0.8183
Complete blood counts						
Mean corpuscular volume, fL	90.6(87.25-93.4);n=122	89.5(85.9-93.3);n=421	0.1331	91.0(87.3-93.8);n=117	89.45(85.8-93.05);n=426	0.0247*
Eosinophil, x10 ⁹ /L	0.1(0.0-0.26);n=113	0.1(0.0-0.2);n=391	0.0387*	0.1(0.0-0.2);n=107	0.1(0.0-0.2);n=397	0.633

Lymphocyte, x10 ⁹ /L	1.1(0.8-1.6);n=113	1.2(0.72-1.7);n=392	0.9579	1.2(0.78-1.7);n=108	1.1(0.8-1.7);n=397	0.3458
Monocyte, x10 ⁹ /L	0.6(0.4-0.8);n=113	0.6(0.4-0.8);n=392	0.385	0.6(0.4-0.7);n=108	0.6(0.4-0.8);n=397	0.6578
Neutrophil, x10 ⁹ /L	5.4(3.9-8.6);n=113	4.8(3.3-7.45);n=392	0.0304*	4.9(3.35-7.9);n=108	4.9(3.4-7.6);n=397	0.7809
White cell count, x10 ⁹ /L	7.45(6.0-10.3);n=122	6.9(5.5-8.8);n=421	0.0383*	6.9(5.6-9.2);n=117	7.05(5.5-9.05);n=426	0.9208
Mean cell haemoglobin, pg	30.85(29.4-32.3);n=122	30.6(28.9-32.0);n=421	0.385	30.9(29.5-32.0);n=117	30.5(28.95-32.0);n=426	0.2106
Platelet, x10 ⁹ /L	196.5(151.5-259.5);n=122	218.0(173.0-280.0);n=421	0.0058**	199.0(163.0-255.0);n=117	216.5(171.5-284.0);n=426	0.022*
Red blood count, x10 ¹² /L	4.02(3.53-4.47);n=122	4.1(3.64-4.62);n=421	0.1079	4.18(3.72-4.53);n=117	4.08(3.57-4.58);n=426	0.4458
<i>Liver and renal functions</i>						
K/Potassium, mmol/L	4.1(3.64-4.4);n=149	4.0(3.7-4.4);n=535	0.8865	4.1(3.8-4.4);n=136	4.0(3.7-4.4);n=548	0.0182*
Urate, mmol/L	0.46(0.36-0.6);n=27	0.33(0.25-0.45);n=73	0.0011**	0.44(0.34-0.55);n=20	0.34(0.26-0.47);n=80	0.0751
Albumin, g/L	35.9(31.4-38.5);n=149	35.9(30.25-40.2);n=532	0.6972	36.75(31.35-41.4);n=134	35.6(30.35-39.8);n=547	0.0835
Na/Sodium,	139.2(135.7-141.7);n=149	138.3(135.1-140.6);n=535	0.0198*	139.55(137.2-142.0);n=13	138.2(134.8-140.7);n=548	0.0023**

mmol/L				6		
Urea, mmol/L	7.22(5.45-11.11);n=149	5.48(4.1-8.1);n=534	<0.0001* **	6.5(4.98-8.43);n=136	5.67(4.1-8.35);n=547	0.0037**
Protein, g/L	70.5(66.1-75.0);n=149	71.2(65.45-75.55);n=532	0.9483	71.35(67.3-75.7);n=134	71.0(65.1-75.35);n=547	0.2734
Creatinine, umol/L	98.0(75.5-145.0);n=148	80.0(63.0-105.5);n=534	<0.0001* **	97.0(73.5-119.5);n=135	80.0(63.0-110.0);n=547	0.0011**
Alkaline phosphatase, U/L	84.0(67.0-125.0);n=149	81.0(64.0-117.0);n=532	0.2434	81.5(66.0-109.5);n=134	82.0(64.0-122.0);n=547	0.5168
Aspartate transaminase, U/L	26.0(18.0-42.9);n=25	40.0(19.0-73.0);n=57	0.0915	22.5(12.5-43.0);n=20	38.5(20.55-62.5);n=62	0.1018
Alanine transaminase, U/L	24.0(16.0-40.0);n=149	24.0(16.0-45.0);n=532	0.777	23.0(16.0-35.0);n=134	25.0(16.0-47.5);n=547	0.0702
Bilirubin, umol/L	13.3(7.4-19.1);n=149	9.95(6.4-16.0);n=532	0.0007** *	12.85(7.4-18.85);n=134	10.0(6.65-16.05);n=547	0.0133*
<i>Lipid and glucose tests</i>						
Triglyceride, mmol/L	0.96(0.76-1.23);n=43	1.02(0.74-1.6);n=124	0.1615	0.9(0.75-1.06);n=28	1.05(0.75-1.52);n=139	0.0387*
Low-density lipoprotein, mmol/L	1.89(1.45-2.57);n=41	2.32(1.69-3.03);n=112	0.0307*	1.69(1.42-2.54);n=27	2.24(1.66-3.03);n=126	0.0274*
High-density lipoprotein,	0.96(0.8-1.31);n=41	1.1(0.85-1.51);n=112	0.1375	1.2(0.79-1.4);n=27	1.06(0.82-1.44);n=126	0.9409

mmol/L						
Cholesterol, mmol/L	3.48(2.7-4.12);n=43	4.0(3.36-4.9);n=124	0.007**	3.43(2.79-4.17);n=28	3.9(3.36-4.86);n=139	0.0173*
HbA1c, g/dL	12.3(10.5-13.5);n=122	12.3(10.9-13.7);n=421	0.3114	12.6(11.3-13.7);n=117	12.1(10.6-13.7);n=426	0.0736
Glucose, mmol/L	6.74(5.38-8.8);n=104	6.35(5.46-7.98);n=363	0.1414	6.73(5.44-8.76);n=95	6.4(5.46-7.91);n=372	0.3817
Cardiac, clotting, inflammator y, and acid-base tests						
D-dimer, ng/mL	2284.52(1223.58-3714.34);n=18	2703.05(1436.46-6951.93);n=55	0.2573	2288.01(1355.12-2315.31);n=5	2738.74(1262.36-6372.09);n=68	0.3764
High sensitive troponin-I, ng/L	0.04(0.02-0.13);n=113	0.02(0.01-0.05);n=331	<0.0001**	0.03(0.01-0.15);n=94	0.02(0.01-0.06);n=350	<0.0001**
Lactate dehydrogenase, U/L	256.0(217.0-335.0);n=119	267.5(207.0-399.0);n=364	0.4864	254.0(213.0-357.0);n=93	267.0(211.0-392.0);n=390	0.6036
APTT, second	34.6(30.55-39.35);n=155	32.8(30.1-35.9);n=566	0.0016**	34.9(30.85-39.95);n=142	32.7(30.1-35.9);n=579	0.0002**
Prothrombin time/INR,	11.9(10.8-14.05);n=155	11.9(10.8-13.65);n=566	0.3178	12.8(10.85-15.15);n=143	11.8(10.8-13.5);n=578	0.0012**

second C-reactive protein, mg/dL	1.94(0.38-7.46);n=136	3.25(0.64-8.99);n=420	0.1109	2.27(0.39-9.39);n=115	3.05(0.73-8.33);n=441	0.5787
ECG measurements						
Trans QRS initangle	46.0(18.5-240.5);n=110	41.0(19.0-86.0);n=464	0.2177	54.0(14.5-318.5);n=96	40.0(19.0-84.5);n=478	0.0481*
Trans QRS initmag	0.38(0.25-0.63);n=110	0.29(0.18-0.46);n=464	0.0003** *	0.36(0.23-0.62);n=96	0.3(0.18-0.49);n=478	0.0128*
Trans QRS max angle	324.0(234.0-342.0);n=110	332.0(26.5-348.0);n=464	0.1915	330.0(288.5-344.5);n=96	331.0(23.5-347.5);n=478	0.7546
Trans QRS max mag	1.33(0.97-2.03);n=110	1.2(0.83-1.62);n=464	0.0013**	1.3(1.02-1.98);n=96	1.21(0.82-1.63);n=478	0.012*
Trans QRS term angle	237.5(214.0-268.0);n=110	244.5(214.5-273.5);n=464	0.1781	240.5(208.0-267.0);n=96	244.5(215.0-273.0);n=478	0.248
Trans QRS term mag	0.36(0.25-0.5);n=110	0.28(0.18-0.39);n=464	<0.0001* **	0.32(0.2-0.48);n=96	0.29(0.19-0.41);n=478	0.1664
Trans QRS cwrot	-100.0(-100.0--36.0);n=110	-100.0(-100.0--100.0);n=464	0.107	-100.0(-100.0--34.5);n=96	-100.0(-100.0--100.0);n=478	0.2777
P wave front axis	56.0(34.5-69.0);n=136	54.0(39.0-68.0);n=662	0.8712	54.0(35.0-70.0);n=113	55.0(39.0-68.0);n=685	0.8949
P wave horizon axis	16.0(-5.0-36.5);n=155	21.0(5.0-37.0);n=675	0.0769	16.0(-3.5-49.5);n=135	21.0(5.0-36.0);n=695	0.91
I 40 front	34.5(2.0-55.0);n=166	39.0(18.0-58.0);n=694	0.0252*	36.5(14.5-58.0);n=154	38.0(15.0-57.5);n=706	0.6716

axis						
I 40 horizon axis	26.0(11.0-43.0);n=161	28.0(12.0-44.0);n=678	0.5733	23.0(10.5-38.0);n=150	29.0(13.0-45.0);n=689	0.0164*
QRS front axis	41.0(0.5-77.5);n=166	55.0(23.0-74.0);n=705	0.0093**	47.0(8.0-76.5);n=155	54.5(22.0-74.0);n=716	0.0621
QRS horizon axis	-12.5(-33.0-10.0);n=164	-11.0(-30.0-8.0);n=689	0.6725	-12.0(-34.0-6.5);n=152	-11.0(-29.0-10.0);n=701	0.4055
T wave 40ms front axis	62.5(-10.0-105.0);n=164	69.5(23.0-100.0);n=698	0.2524	69.0(7.0-101.0);n=153	69.0(20.0-102.0);n=709	0.6981
T wave 40ms horizon axis	-21.0(-56.0-222.0);n=158	-23.0(-51.0-157.0);n=671	0.3101	-20.0(-55.5-229.5);n=144	-23.0(-51.0-163.0);n=685	0.4783
ST segment front axis	83.0(22.0-168.0);n=153	61.0(30.5-101.0);n=674	0.0223*	76.5(38.5-162.5);n=144	62.0(29.0-105.0);n=683	0.0207*
ST segment horizon axis	99.0(65.0-161.0);n=143	71.0(48.0-107.0);n=637	<0.0001**	96.5(66.5-145.0);n=136	72.5(47.0-110.0);n=644	<0.0001**
T wave front axis	52.0(10.0-105.0);n=161	44.0(14.5-68.5);n=696	0.0378*	43.0(11.5-72.5);n=150	45.0(15.0-71.0);n=707	0.5477
T wave horizon axis	63.0(26.0-108.5);n=155	44.0(25.0-71.0);n=650	0.0014**	46.5(25.0-79.5);n=142	46.0(24.5-75.0);n=663	0.6236
Atrialrate	81.0(67.0-102.5);n=168	80.0(66.0-99.0);n=706	0.2339	79.0(64.0-102.5);n=156	80.5(67.0-99.0);n=718	0.8544
Mean ventricular rate	80.5(67.5-94.0);n=168	81.0(68.0-98.0);n=706	0.4043	77.5(67.5-89.0);n=156	82.0(68.0-98.0);n=718	0.0451*
Mean PT interval	166.0(152.0-186.0);n=168	160.0(144.0-176.0);n=706	0.0001**	172.0(154.0-192.0);n=156	160.0(144.0-176.0);n=718	<0.0001**
Mean PR	68.0(53.0-86.5);n=168	62.0(48.0-75.0);n=706	0.0012**	74.0(58.0-88.5);n=156	61.0(48.0-74.5);n=718	<0.0001*

segment						**
Mean QRS duration	90.0(80.0-101.5);n=168	84.0(78.0-94.0);n=706	<0.0001* **	88.0(81.5-96.0);n=156	84.0(78.0-94.5);n=718	0.0059**
Mean QT interval	395.5(362.5-422.0);n=168	374.0(343.0-408.0);n=706	<0.0001* **	395.5(360.0-417.0);n=156	376.0(343.0-408.0);n=718	0.0002** *
Mean QTc	447.0(423.5-474.5);n=168	431.0(410.0-456.0);n=706	<0.0001* **	443.5(420.5-463.0);n=156	432.0(411.0-457.0);n=718	0.0022**
QT interval dispersion	77.0(0.0-119.0);n=168	63.0(0.0-101.5);n=706	0.0899	60.0(0.0-96.0);n=156	66.0(0.0-104.0);n=718	0.3777

COPD: chronic obstructive pulmonary disease; ACEI: angiotensinogen converting enzyme inhibitor; ARB: angiotensin receptor blocker; APTT: activated partial thromboplastin time.

Table 3. Univariate Cox analysis of significant risk factors to predict spontaneous VT/VF, new onset HF and new onset AF.

* for $p \leq 0.05$, ** for $p \leq 0.01$, *** for $p \leq 0.001$

Characteristics	Spontaneous VT/VF HR [95% CI];P value	Cutoff	New onset HF HR [95% CI];P value	Cutoff	New onset AF HR [95% CI];P value	Cutoff
<i>Demographics</i>						
Male gender	0.84[0.50-1.42];0.5177	-	0.91[0.67-1.25];0.5643	-	0.95[0.68-1.31];0.7399	-
Female gender	1.19[0.70-2.01];0.5177	-	1.10[0.80-1.50];0.5643	-	1.06[0.76-1.46];0.7399	-
Baseline age, years	1.00[0.98-1.01];0.6879	35.13	1.04[1.03-1.05];<0.0001***	77.11	1.04[1.03-1.06];<0.0001***	49.46
<40	1.55[0.82-2.93];0.1808	-	0.35[0.18-0.66];0.0013**	-	0.07[0.02-0.27];0.0001***	-
[40, 50)	0.64[0.26-1.60];0.3409	-	0.42[0.22-0.80];0.0085**	-	0.29[0.14-0.63];0.0016**	-
[50-60)	0.86[0.46-1.61];0.6421	-	0.58[0.38-0.87];0.0094**	-	0.98[0.68-1.42];0.9185	-
[60-70)	1.09[0.59-1.99];0.7835	-	1.45[1.03-2.03];0.0328*	-	1.74[1.24-2.45];0.0015**	-
[70-80)	1.19[0.60-2.36];0.6219	-	1.62[1.11-2.35];0.0121*	-	1.87[1.28-2.74];0.0013**	-
≥ 80	0.50[0.12-2.06];0.3382	-	3.40[2.27-5.10];<0.0001***	-	1.93[1.18-3.16];0.0093**	-
<i>Past comorbidities</i>						
Baseline VT/VF	13.06[4.70-36.28];<0.0001***	-	2.12[0.68-6.65];0.1967	-	0.66[0.09-4.70];0.6754	-
Cerebrovascular disease	1.12[0.27-4.58];0.8790	-	1.96[1.00-3.84];0.0504	-	1.59[0.74-3.39];0.2346	-
Rheumatic disease	2.21[0.80-6.14];0.1269	-	0.84[0.31-2.26];0.7284	-	0.56[0.18-1.75];0.3153	-
Renal diseases	0.88[0.28-2.83];0.8364	-	1.55[0.90-2.69];0.1158	-	1.17[0.63-2.17];0.6117	-
Diabetes mellitus	1.99[0.62-6.37];0.2471	-	2.55[1.34-4.83];0.0043**	-	1.50[0.66-3.40];0.3321	-
Hypertension	1.21[0.62-2.34];0.5752	-	2.73[1.96-3.80];<0.0001***	-	1.61[1.10-2.35];0.0149*	-
Malignant dysrhythmia	9.05[3.60-22.70];<0.0001***	-	1.65[0.61-4.44];0.3254	-	1.36[0.43-4.27];0.5977	-
AMI	-	-	2.51[1.18-5.36];0.0174*	-	1.19[0.44-3.23];0.7280	-
COPD	2.10[0.29-15.19];0.4622	-	2.27[0.72-7.12];0.1600	-	0.72[0.10-5.13];0.7410	-

IHD	1.04[0.45-2.42];0.9293	-	2.04[1.35-3.08];0.0008***	-	1.49[0.94-2.36];0.0935	-
PVD	1.20[0.17-8.69];0.8557	-	1.67[0.62-4.50];0.3135	-	1.41[0.45-4.43];0.5563	-
Stroke/TIA	1.22[0.30-5.02];0.7803	-	1.64[0.77-3.51];0.1988	-	1.78[0.83-3.81];0.1352	-
Gastrointestinal bleeding	0.90[0.22-3.68];0.8804	-	1.58[0.83-2.99];0.1628	-	1.59[0.81-3.11];0.1801	-
Immune mediated enterocolitis	0.62[0.15-2.54];0.5065	-	0.74[0.35-1.58];0.4382	-	0.70[0.31-1.58];0.3893	-
Anxiety disorder and depression	0.94[0.13-6.77];0.9478	-	2.73[1.28-5.83];0.0095**	-	0.74[0.18-3.01];0.6789	-
SCD	0.82[0.11-5.92];0.8431	-	2.26[1.06-4.82];0.0355*	-	1.10[0.41-2.98];0.8475	-
Atrial flutter	-	-	1.07[0.15-7.62];0.9485	-	5.61[2.07-15.20];0.0007***	-
Accident fall	1.03[0.32-3.30];0.9617	-	1.25[0.67-2.30];0.4828	-	1.71[0.95-3.08];0.0761	-
Malignancy	1.04[0.49-2.21];0.9208	-	0.32[0.16-0.63];0.0010**	-	0.50[0.27-0.90];0.0202*	-
Metastatic solid tumor	0.63[0.15-2.62];0.5274	-	0.46[0.19-1.12];0.0873	-	0.52[0.21-1.28];0.1530	-
Medications						
ACEI	1.27[0.58-2.81];0.5525	-	1.98[1.31-2.99];0.0013**	-	1.30[0.80-2.11];0.2826	-
ARB	2.13[0.85-5.35];0.1074	-	1.33[0.68-2.60];0.4116	-	1.45[0.74-2.85];0.2802	-
Lipid-lowering drugs	-	-	-	-	-	-
Anticoagulants	1.57[0.81-3.05];0.1776	-	1.80[1.23-2.65];0.0026**	-	1.38[0.90-2.11];0.1355	-
Insulin	-	-	-	-	-	-
Incretin mimetics	1.31[0.18-9.50];0.7869	-	2.26[0.84-6.11];0.1069	-	0.47[0.07-3.33];0.4469	-
Complete blood counts						
Mean corpuscular volume, fL	0.98[0.94-1.01];0.2003	90	1.02[0.99-1.04];0.1297	95	1.02[0.99-1.04];0.1925	90.7
Eosinophil, x10 ⁹ /L	1.52[0.81-2.86];0.1902	0.17	1.38[0.97-1.97];0.0773	0.19	0.97[0.53-1.75];0.9094	0.09

Lymphocyte, x10 ⁹ /L	0.82[0.50-1.34];0.4210	1.1	0.90[0.70-1.15];0.3919	1.15	0.99[0.78-1.25];0.9186	0.6
Monocyte, x10 ⁹ /L	1.37[0.94-1.99];0.1023	0.65	1.40[1.13-1.75];0.0025**	0.49	1.03[0.72-1.49];0.8588	0.47
Neutrophil, x10 ⁹ /L	0.98[0.89-1.08];0.7162	4.9	1.06[1.01-1.11];0.0084**	4.7	1.04[0.99-1.09];0.1068	6.3
White cell count, x10 ⁹ /L	1.07[0.99-1.16];0.0963	6.4	1.07[1.03-1.12];0.0017**	8.3	1.01[0.96-1.07];0.7197	8.2
Mean cell haemoglobin, pg	0.94[0.86-1.03];0.1745	30.6	1.02[0.96-1.08];0.4921	33.4	1.02[0.96-1.08];0.5375	30.4
Platelet, x10 ⁹ /L	1.002[0.998-1.005];0.3552	155	0.997[0.995-0.999];0.0135*	215	0.998[0.996-1.000];0.0943	275
Red blood count, x10 ¹² /L	0.83[0.55-1.26];0.3890	3.4	0.76[0.61-0.95];0.0180*	3.97	1.04[0.82-1.32];0.7469	3.62
<i>Liver and renal functions</i>						
K/Potassium, mmol/L	0.90[0.57-1.43];0.6644	3.5	0.99[0.76-1.30];0.9640	3.64	1.27[0.98-1.64];0.0716	3.8
Urate, mmol/L	1.92[0.07-50.43];0.6952	0.57	34.00[3.86-299.69];0.0015**	0.43	3.17[0.25-40.88];0.3769	0.41
Albumin, g/L	0.98[0.94-1.01];0.2225	39.8	0.98[0.96-1.00];0.1147	39.7	1.00[0.97-1.02];0.8670	25.3
Na/Sodium, mmol/L	0.99[0.93-1.05];0.7526	141.2	1.02[0.98-1.06];0.3282	141.1	1.05[1.00-1.09];0.0366*	141.8
Urea, mmol/L	1.01[0.97-1.04];0.7378	11.89	1.02[1.01-1.03];0.0053**	6.6	1.01[0.99-1.03];0.4214	4.11
Protein, g/L	0.99[0.96-1.02];0.5079	77.2	0.99[0.97-1.01];0.5958	77.6	1.00[0.98-1.02];0.9728	66.4
Creatinine, umol/L	1.000[0.999-1.001];0.6363	60	1.000[1.000-1.001];0.5454	122	1.000[0.999-1.001];0.9813	85
Alkaline phosphatase, U/L	1.00[1.00-1.01];0.3039	67	1.001[0.999-1.004];0.3772	65	1.000[0.997-1.003];0.8691	63
Aspartate transaminase, U/L	1.001[0.999-1.002];0.2601	21	0.99[0.97-1.00];0.1255	49	1.000[0.998-1.001];0.6384	23
Alanine transaminase, U/L	1.000[0.999-1.001];0.7930	15.9	1.001[1.000-1.001];0.0027**	91	1.00[0.99-1.00];0.2503	49

Bilirubin, umol/L	0.99[0.97-1.02];0.6014	7.8	1.01[1.00-1.01];0.0002***	12.3	1.01[1.01-1.02];<0.0001***	12
<i>Lipid and glucose tests</i>						
Triglyceride, mmol/L	1.76[0.84-3.68];0.1323	1.21	0.61[0.34-1.11];0.1053	1.69	0.37[0.15-0.90];0.0281*	1.23
Low-density lipoprotein, mmol/L	0.97[0.54-1.74];0.9228	1.2109	0.66[0.45-0.95];0.0273*	2.1173	0.65[0.40-1.04];0.0724	2.7855
High-density lipoprotein, mmol/L	0.19[0.04-0.94];0.0415*	1.09	0.56[0.28-1.14];0.1109	1.56	0.96[0.42-2.19];0.9242	1.18
Cholesterol, mmol/L	0.99[0.65-1.52];0.9722	4.03	0.70[0.53-0.93];0.0126*	4.7	0.68[0.47-0.97];0.0343*	3.6
HbA1c, g/dL	0.90[0.78-1.04];0.1583	11.4	0.92[0.85-1.00];0.0464*	9.7	1.03[0.95-1.13];0.4444	10.8
Glucose, mmol/L	0.96[0.86-1.07];0.4460	5.17	1.05[1.01-1.09];0.0165*	6.64	1.03[0.98-1.07];0.2317	7.79
<i>Cardiac, clotting, inflammatory, and acid-base tests</i>						
D-dimer, ng/mL	1.000[1.000-1.000];0.8538	1676.12	1.000[1.000-1.000];0.2234	6329.5498	1.000[1.000-1.000];0.9549	2315.31
High sensitive troponin-I, ng/L	0.99[0.90-1.08];0.7459	0.0199	1.01[1.00-1.02];0.1592	0.0179	1.00[0.98-1.02];0.9476	0.0114
Lactate dehydrogenase, U/L	1.001[1.000-1.002];0.0554	409	1.000[0.999-1.001];0.8341	218	1.001[1.000-1.001];0.1068	223
APTT, second	1.01[0.99-1.03];0.3782	33.9	1.01[1.00-1.02];0.0073**	39.5	1.02[1.01-1.03];<0.0001***	39.5
Prothrombin time/INR, second	1.00[0.96-1.05];0.8719	10.1	1.03[1.01-1.05];0.0030**	16.1	1.04[1.02-1.06];0.0002***	12.7
C-reactive protein, mg/dL	1.01[0.97-1.05];0.5465	1.739	1.00[0.97-1.02];0.8999	4.175	1.01[0.99-1.03];0.4155	5.975
<i>ECG measurements</i>						
Trans QRS initangle	1.000[0.997-1.003];0.8486	21	1.002[1.001-1.004];0.0037**	205	1.003[1.001-1.004];0.0002***	251
Trans QRS initmag	0.66[0.18-2.40];0.5259	0.11	2.77[1.67-4.60];0.0001***	0.75	2.03[1.09-3.77];0.0257*	0.582

Trans QRS max angle	1.000[0.997-1.002];0.7373	220	1.001[0.999-1.002];0.3282	351	1.001[1.000-1.003];0.0752	7
Trans QRS max mag	0.70[0.39-1.24];0.2230	1.322	1.43[1.08-1.90];0.0131*	2.16	1.23[0.91-1.67];0.1847	1.97
Trans QRS term angle	1.00[0.99-1.00];0.0444*	234	1.00[0.99-1.00];0.1175	225	0.999[0.996-1.002];0.5706	257
Trans QRS term mag	1.74[0.55-5.46];0.3432	0.592	2.70[1.55-4.68];0.0004***	0.49	1.58[0.76-3.30];0.2220	0.45
Trans QRS cwrot	1.00[1.00-1.01];0.5411	-34	1.00[1.00-1.01];0.2545	-50	1.00[1.00-1.01];0.4167	-45
P wave front axis	1.00[0.99-1.01];0.7611	75	1.00[1.00-1.01];0.6109	15	1.00[1.00-1.01];0.2615	75
P wave horizon axis	1.00[0.99-1.00];0.2539	-18	1.00[1.00-1.01];0.2775	-15	1.01[1.00-1.01];0.0002***	53
I 40 front axis	1.00[0.99-1.00];0.3288	-4	0.99[0.99-1.00];0.0242*	7	1.00[0.99-1.00];0.1402	26
I 40 horizon axis	1.01[1.00-1.01];0.0587	-3	1.00[1.00-1.01];0.2961	29	0.99[0.99-1.00];0.0172*	29
QRS front axis	1.00[0.99-1.00];0.5589	-12	0.99[0.99-1.00];0.0017**	2	1.00[0.99-1.00];0.0128*	-2
QRS horizon axis	1.00[1.00-1.01];0.7183	-48	1.002[0.999-1.004];0.2684	-50	0.999[0.995-1.002];0.4450	-30
T wave 40ms front axis	1.001[0.998-1.005];0.4056	103	0.999[0.996-1.001];0.2277	-8	0.999[0.997-1.002];0.5548	-41
T wave 40ms horizon axis	1.002[1.000-1.004];0.1059	15	1.002[1.000-1.003];0.0131*	91	1.001[1.000-1.002];0.0744	226
ST segment front axis	1.001[0.997-1.004];0.7597	105	1.002[1.000-1.004];0.0214*	108	1.00[1.00-1.01];0.0011**	106
ST segment horizon axis	1.00[1.00-1.01];0.2457	149	1.01[1.00-1.01];<0.0001***	162	1.01[1.00-1.01];0.0001***	90
T wave front axis	1.00[1.00-1.01];0.1033	22	1.00[1.00-1.01];0.0032**	80	1.000[0.997-1.002];0.8900	28
T wave horizon axis	1.000[0.996-1.005];0.8465	16	1.00[1.00-1.01];0.0208*	59	1.000[0.997-1.003];0.8419	70
Atrialrate	1.00[0.99-1.00];0.4626	71	1.00[1.00-1.01];<0.0001***	116	1.01[1.00-1.01];<0.0001***	118
Mean ventricular rate	1.01[1.00-1.02];0.1893	77	1.00[1.00-1.01];0.4141	78	1.00[0.99-1.01];0.9446	103
Mean PT interval	1.00[0.99-1.01];0.8872	162	1.01[1.00-1.01];0.0006***	195	1.01[1.01-1.02];<0.0001***	176
Mean PR segment	1.00[0.98-1.01];0.4562	56	1.01[1.00-1.01];0.0046**	90	1.01[1.01-1.02];<0.0001***	76
Mean QRS duration	1.01[1.00-1.03];0.0171*	93	1.02[1.01-1.02];<0.0001***	103	1.01[1.00-1.01];0.0666	77
Mean QT interval	1.00[0.99-1.01];0.9214	338	1.01[1.00-1.01];0.0011**	391	1.00[1.00-1.01];0.0051**	392

Mean QTc	1.01[1.00-1.02];0.0035**	413	1.01[1.01-1.02];<0.0001***	466	1.01[1.00-1.01];0.0001***	445
QT interval dispersion	1.001[0.997-1.005];0.7497	34	1.00[1.00-1.01];0.0004***	77	1.002[1.000-1.005];0.0868	43

COPD: chronic obstructive pulmonary disease; ACEI: angiotensinogen converting enzyme inhibitor; ARB: angiotensin receptor blocker; APTT: activated partial thromboplastin time.

Table 4. Univariate Cox analysis of significant risk factors to predict cardiovascular mortality and all-cause mortality.

* for $p \leq 0.05$, ** for $p \leq 0.01$, *** for $p \leq 0.001$

Characteristics	Cardiovascular mortality HR [95% CI];P value	Cutoff	Mortality HR [95% CI];P value	Cutoff
Demographics				
Male gender	0.88[0.50-1.55];0.6610	-	0.86[0.70-1.05];0.1319	-
Female gender	1.13[0.65-1.99];0.6610	-	1.16[0.96-1.42];0.1319	-
Baseline age, years	1.04[1.02-1.06];0.0001***	74.75	1.02[1.02-1.03];<0.0001***	73.83
<40	0.71[0.30-1.68];0.4371	-	0.43[0.29-0.62];<0.0001***	-
[40, 50)	0.13[0.02-0.94];0.0433*	-	0.70[0.51-0.98];0.0383*	-
[50-60)	0.54[0.25-1.15];0.1120	-	0.97[0.77-1.22];0.7821	-
[60-70)	0.98[0.50-1.93];0.9641	-	1.06[0.84-1.34];0.6078	-
[70-80)	2.37[1.27-4.42];0.0064**	-	1.53[1.20-1.95];0.0005***	-
≥ 80	3.48[1.68-7.22];0.0008***	-	1.89[1.39-2.57];0.0001***	-
Charlson standard comorbidity index	1.21[1.10-1.33];0.0001***	2	1.27[1.24-1.31];<0.0001***	4
Past comorbidities				
Baseline VT/VF	2.17[0.30-15.71];0.4444	-	0.76[0.24-2.36];0.6302	-
Cerebrovascular disease	4.31[1.83-10.15];0.0008***	-	0.97[0.54-1.71];0.9037	-
Rheumatic disease	1.10[0.27-4.53];0.8979	-	0.44[0.20-1.00];0.0486*	-

Renal diseases	2.14[0.91-5.03];0.0810	-	1.24[0.85-1.82];0.2576	-
Diabetes mellitus	0.82[0.11-5.95];0.8443	-	1.43[0.85-2.40];0.1747	-
Hypertension	2.92[1.61-5.28];0.0004***	-	1.55[1.23-1.96];0.0002***	-
Malignant dysrhythmia	2.41[0.58-9.92];0.2246	-	0.76[0.31-1.83];0.5367	-
AMI	1.07[0.15-7.74];0.9485	-	1.35[0.74-2.46];0.3277	-
COPD	2.61[0.36-18.95];0.3428	-	1.82[0.81-4.08];0.1462	-
IHD	1.21[0.51-2.84];0.6669	-	0.95[0.68-1.32];0.7422	-
PVD	2.84[0.69-11.71];0.1488	-	1.04[0.47-2.34];0.9178	-
Stroke/TIA	3.91[1.55-9.88];0.0039**	-	0.88[0.47-1.65];0.6858	-
Gastrointestinal bleeding	1.63[0.51-5.23];0.4148	-	1.77[1.20-2.62];0.0042**	-
Immune mediated enterocolitis	0.64[0.16-2.65];0.5425	-	0.73[0.45-1.19];0.2046	-
Anxiety disorder and depression	1.08[0.15-7.85];0.9371	-	0.91[0.43-1.91];0.7957	-
SCD	1.00[0.14-7.26];1.0000***	-	1.49[0.86-2.59];0.1577	-
Atrial flutter	0.00[0.00-Inf];0.9960	-	0.66[0.16-2.64];0.5556	-
Accident fall	2.82[1.20-6.64];0.0179*	-	1.15[0.76-1.76];0.5055	-
Malignancy	0.83[0.33-2.10];0.6902	-	3.27[2.64-4.05];<0.0001***	-
Metastatic solid tumor	0.00[0.00-Inf];0.9963	-	6.12[4.75-7.89];<0.0001***	-
<i>Medications</i>				
ACEI	0.95[0.38-2.40];0.9146	-	0.60[0.41-0.90];0.0128*	-
ARB	0.40[0.06-2.90];0.3647	-	0.21[0.08-0.56];0.0020**	-
Lipid-lowering drugs	-	-	-	-
Anticoagulants	0.68[0.27-1.70];0.4060	-	0.49[0.33-0.71];0.0002***	-
Insulin	-	-	-	-
Incretin mimetics	1.35[0.19-9.79];0.7664	-	0.70[0.26-1.87];0.4719	-
<i>Complete blood counts</i>				

Mean corpuscular volume, fL	0.99[0.95-1.03];0.6814	87	0.99[0.98-1.01];0.4169	97
Eosinophil, x10 ⁹ /L	1.07[0.36-3.19];0.9060	0.28	0.84[0.52-1.35];0.4723	0.02
Lymphocyte, x10 ⁹ /L	1.13[0.79-1.63];0.5080	0.67	0.62[0.50-0.76];<0.0001***	1.1
Monocyte, x10 ⁹ /L	1.09[0.51-2.31];0.8276	0.35	1.26[1.06-1.48];0.0072**	0.73
Neutrophil, x10 ⁹ /L	0.98[0.88-1.09];0.6727	3.2	1.03[1.00-1.07];0.0388*	6.5
White cell count, x10 ⁹ /L	1.08[0.98-1.18];0.1135	6.7	1.09[1.05-1.12];<0.0001***	8.2
Mean cell haemoglobin, pg	0.96[0.87-1.07];0.4730	31.5	0.98[0.95-1.02];0.3270	29
Platelet, x10 ⁹ /L	1.001[0.998-1.005];0.4143	181	1.001[1.000-1.003];0.0422*	318
Red blood count, x10 ¹² /L	0.70[0.46-1.08];0.1044	3.4	0.71[0.61-0.83];<0.0001***	3.97
<i>Liver and renal functions</i>				
K/Potassium, mmol/L	1.17[0.73-1.85];0.5151	4.38	1.10[0.93-1.32];0.2650	4.32
Urate, mmol/L	19.54[0.62-615.16];0.0912	0.46	0.95[0.20-4.56];0.9447	0.24
Albumin, g/L	0.96[0.92-1.00];0.0656	39.4	0.95[0.94-0.97];<0.0001***	37.3
Na/Sodium, mmol/L	1.02[0.95-1.09];0.6241	134.14	0.93[0.91-0.95];<0.0001***	137
Urea, mmol/L	1.02[1.00-1.05];0.0401*	13.32	1.01[0.99-1.02];0.3426	8.26
Protein, g/L	0.97[0.94-1.01];0.1176	77.2	0.98[0.96-0.99];0.0003***	67.6
Creatinine, umol/L	1.001[1.000-1.001];0.1034	97	1.000[0.999-1.000];0.4670	61
Alkaline phosphatase, U/L	1.00[0.99-1.00];0.3722	144	1.00[1.00-1.01];<0.0001***	63
Aspartate transaminase, U/L	1.001[1.000-1.002];0.1801	21	1.001[1.000-1.001];0.0476*	91
Alanine transaminase, U/L	1.000[0.999-1.002];0.9668	40	1.000[1.000-1.001];<0.0001***	63
Bilirubin, umol/L	1.00[0.99-1.02];0.6439	20.3	1.00[1.00-1.01];0.1075	20.3
<i>Lipid and glucose tests</i>				
Triglyceride, mmol/L	0.72[0.25-2.11];0.5507	1.86	0.73[0.46-1.17];0.1965	1.69
Low-density lipoprotein, mmol/L	1.07[0.61-1.89];0.8039	3.25	0.97[0.74-1.28];0.8528	2.0818
High-density lipoprotein, mmol/L	1.17[0.34-3.96];0.8022	1.32	1.08[0.61-1.93];0.7833	1.62

Cholesterol, mmol/L	1.04[0.65-1.65];0.8796	5.3	0.96[0.77-1.18];0.6876	2.69
HbA1c, g/dL	0.87[0.75-1.00];0.0544	10.3	0.86[0.82-0.91];<0.0001***	14
Glucose, mmol/L	1.03[0.96-1.11];0.4344	7.88	1.02[0.99-1.05];0.2468	8.29
<i>Cardiac, clotting, inflammatory, and acid-base tests</i>				
D-dimer, ng/mL	1.000[1.000-1.001];0.0639	4712.05	1.000[1.000-1.000];0.0406*	779.18
High sensitive troponin-I, ng/L	0.99[0.91-1.08];0.8063	0.0408	1.00[0.99-1.02];0.7900	0.0814
Lactate dehydrogenase, U/L	1.000[0.999-1.002];0.5729	355	1.001[1.001-1.001];<0.0001***	390
APTT, second	1.01[0.98-1.03];0.5725	30.7	0.99[0.97-1.00];0.0446*	27.7
Prothrombin time/INR, second	0.99[0.94-1.05];0.8329	11	1.01[0.99-1.02];0.5410	11.4
C-reactive protein, mg/dL	0.98[0.93-1.04];0.4918	0.121	1.02[1.00-1.03];0.0631	0.879
<i>ECG measurements</i>				
Trans QRS initangle	1.000[0.996-1.003];0.8833	17	0.999[0.998-1.001];0.3597	13
Trans QRS initmag	4.73[1.88-11.88];0.0009***	0.467	0.70[0.43-1.14];0.1530	0.15
Trans QRS max angle	1.000[0.997-1.003];0.8348	344	1.000[0.999-1.001];0.5058	271
Trans QRS max mag	0.89[0.46-1.70];0.7180	1.02	0.47[0.37-0.59];<0.0001***	1.027
Trans QRS term angle	0.99[0.99-1.00];0.0219*	209	0.999[0.997-1.001];0.4206	298
Trans QRS term mag	1.73[0.45-6.57];0.4224	0.592	0.31[0.15-0.61];0.0007***	0.282
Trans QRS cwrot	1.01[1.00-1.01];0.0837	-100	1.000[0.998-1.003];0.8687	-17
P wave front axis	1.00[0.99-1.01];0.7101	20	1.001[0.998-1.004];0.5060	15
P wave horizon axis	1.00[1.00-1.01];0.4592	44	0.999[0.997-1.001];0.3760	53
I 40 front axis	1.00[1.00-1.01];0.3348	70	0.999[0.996-1.002];0.5154	10
I 40 horizon axis	1.01[1.00-1.01];0.0088**	15	1.000[0.997-1.003];0.9221	16
QRS front axis	0.99[0.99-1.00];0.0553	14	1.001[0.999-1.003];0.2077	91
QRS horizon axis	1.00[1.00-1.01];0.4944	34	0.999[0.997-1.001];0.4607	-15

T wave 40ms front axis	1.000[0.996-1.004];0.8801	-20	1.000[0.999-1.001];0.9945	-31
T wave 40ms horizon axis	1.00[1.00-1.01];0.0006***	28	1.001[1.000-1.002];0.0160*	83
ST segment front axis	1.001[0.997-1.005];0.6429	-16	1.000[0.999-1.001];0.8069	-19
ST segment horizon axis	1.00[1.00-1.01];0.1008	145	0.999[0.997-1.001];0.4976	57
T wave front axis	1.00[1.00-1.01];0.3781	-15	1.000[0.998-1.001];0.9074	-16
T wave horizon axis	1.00[1.00-1.01];0.4924	66	0.999[0.997-1.001];0.3152	40
Atrialrate	1.00[1.00-1.01];0.5720	87	1.001[1.000-1.003];0.1378	87
Mean ventricular rate	1.00[0.99-1.01];0.9165	58	1.01[1.01-1.02];<0.0001***	88
Mean PT interval	1.00[0.99-1.01];0.6172	147	0.99[0.99-1.00];<0.0001***	160
Mean PR segment	1.00[0.99-1.01];0.6084	89	0.99[0.99-1.00];0.0006***	56
Mean QRS duration	1.02[1.01-1.03];0.0004***	99	1.00[1.00-1.01];0.8309	74
Mean QT interval	1.00[1.00-1.01];0.1896	354	1.00[0.99-1.00];0.0012**	380
Mean QTc	1.01[1.00-1.01];0.0374*	431	1.01[1.00-1.01];0.0001***	423
QT interval dispersion	1.000[0.995-1.005];0.9536	113	1.002[1.000-1.003];0.0136*	92

COPD: chronic obstructive pulmonary disease; ACEI: angiotensinogen converting enzyme inhibitor; ARB: angiotensin receptor blocker; APTT: activated partial thromboplastin time.

Figure 1. Procedures of data processing.

Figure 2. Survival curves of adverse primary and secondary outcomes in pericarditis patients.

Figure 3. Gender-specific ECG measurements with/without VT/VF, new onset HF and new onset AF.